BioCentury | Mar 7, 2020
Translation in Brief

Repurposing a protease inhibitor for COVID-19; plus City of Hope’s scorpion venom CAR T and Blaze’s tech for tissue-targeted steroid delivery

Protease inhibitor blocks COVID-19 viral fusion  Camostat mesylate, a TMPRSS2 inhibitor already approved in Japan for digestive system indications, has become one of the latest drugs that could be repurposed to treat COVID-19. A team...
BioCentury | Feb 12, 2020
Tools & Techniques

NCATS, FDA meeting shines light on AAV manufacturing innovation

Technologies highlighted at a NCATS-FDA AAV manufacturing workshop could ramp up the production and durability of gene therapies, but questions remain about who will test drive these innovations and where the next wave of them...
BioCentury | Dec 14, 2019
Product Development

BCMA programs begin to find their niches

As CAR Ts, bispecifics and ADCs targeting BCMA battle it out in multiple myeloma, the question is not which modality will win, but whether they can fill different niches in the treatment landscape. The safety...
BC Extra | Nov 7, 2019
Clinical News

ALS group launches trial of digital app to track progression

A new mobile app could help patients, physicians and drug developers track amyotrophic lateral sclerosis disease progression to better understand whether an investigational therapy is working and learn more about the natural history of the...
BC Extra | Sep 30, 2019
Clinical News

Stable disease signal pushes Amgen KRAS inhibitor forward in colorectal cancer

Despite a far lower partial response rate in colorectal cancer than in lung cancer, Amgen plans to expand its colorectal trials and gear up for combination studies of closely watched KRAS inhibitor AMG 510, citing...
BC Innovations | Sep 25, 2019
Targets & Mechanisms

Switching targets to avoid resistance to CAR Ts

City of Hope researchers have engineered CAR T cells directed against a new B cell target that could overcome resistance to or replace canonical CAR Ts. The novel CAR T therapy against TNFRSF13c, which was...
BC Extra | Aug 13, 2019
Company News

Aug. 13 Company Quick Takes: Pharming licenses Novartis' CDZ173; plus Novartis, Merck-Harvard, Mustang, J&J

Pharming licenses Novartis autoimmune candidate  Pharming Group N.V. (Euronext:PHARM) gained rights to PI3Kδ inhibitor CDZ173 from Novartis AG (NYSE:NVS; SIX:NOVN) for patients with activated PI3Kδ syndrome, a primary immune deficiency. Novartis will receive $20 million...
BC Innovations | Aug 8, 2019
Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

Akrevia is harnessing proteases to mask biologics in the periphery and switch them on when they reach the tumor environment to deliver highly immunostimulatory antibodies, cytokines and other immunotherapies that are otherwise toxic to tissues....
BC Innovations | Jul 24, 2019
Translation in Brief

Unraveling checkpoint responses in PD-L1-negative cancers

A new study from City of Hope offers a long-sought explanation for why some patients lacking PD-L1 expression on their tumors respond to antibodies against the target, and uncovers a way to boost NK cell...
BC Innovations | Jun 5, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

New Therapeutic Targets and Biomarkers: May 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May. Therapeutic targets are defined as any protein, gene or other molecule...
Items per page:
1 - 10 of 231
BioCentury | Mar 7, 2020
Translation in Brief

Repurposing a protease inhibitor for COVID-19; plus City of Hope’s scorpion venom CAR T and Blaze’s tech for tissue-targeted steroid delivery

Protease inhibitor blocks COVID-19 viral fusion  Camostat mesylate, a TMPRSS2 inhibitor already approved in Japan for digestive system indications, has become one of the latest drugs that could be repurposed to treat COVID-19. A team...
BioCentury | Feb 12, 2020
Tools & Techniques

NCATS, FDA meeting shines light on AAV manufacturing innovation

Technologies highlighted at a NCATS-FDA AAV manufacturing workshop could ramp up the production and durability of gene therapies, but questions remain about who will test drive these innovations and where the next wave of them...
BioCentury | Dec 14, 2019
Product Development

BCMA programs begin to find their niches

As CAR Ts, bispecifics and ADCs targeting BCMA battle it out in multiple myeloma, the question is not which modality will win, but whether they can fill different niches in the treatment landscape. The safety...
BC Extra | Nov 7, 2019
Clinical News

ALS group launches trial of digital app to track progression

A new mobile app could help patients, physicians and drug developers track amyotrophic lateral sclerosis disease progression to better understand whether an investigational therapy is working and learn more about the natural history of the...
BC Extra | Sep 30, 2019
Clinical News

Stable disease signal pushes Amgen KRAS inhibitor forward in colorectal cancer

Despite a far lower partial response rate in colorectal cancer than in lung cancer, Amgen plans to expand its colorectal trials and gear up for combination studies of closely watched KRAS inhibitor AMG 510, citing...
BC Innovations | Sep 25, 2019
Targets & Mechanisms

Switching targets to avoid resistance to CAR Ts

City of Hope researchers have engineered CAR T cells directed against a new B cell target that could overcome resistance to or replace canonical CAR Ts. The novel CAR T therapy against TNFRSF13c, which was...
BC Extra | Aug 13, 2019
Company News

Aug. 13 Company Quick Takes: Pharming licenses Novartis' CDZ173; plus Novartis, Merck-Harvard, Mustang, J&J

Pharming licenses Novartis autoimmune candidate  Pharming Group N.V. (Euronext:PHARM) gained rights to PI3Kδ inhibitor CDZ173 from Novartis AG (NYSE:NVS; SIX:NOVN) for patients with activated PI3Kδ syndrome, a primary immune deficiency. Novartis will receive $20 million...
BC Innovations | Aug 8, 2019
Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

Akrevia is harnessing proteases to mask biologics in the periphery and switch them on when they reach the tumor environment to deliver highly immunostimulatory antibodies, cytokines and other immunotherapies that are otherwise toxic to tissues....
BC Innovations | Jul 24, 2019
Translation in Brief

Unraveling checkpoint responses in PD-L1-negative cancers

A new study from City of Hope offers a long-sought explanation for why some patients lacking PD-L1 expression on their tumors respond to antibodies against the target, and uncovers a way to boost NK cell...
BC Innovations | Jun 5, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

New Therapeutic Targets and Biomarkers: May 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May. Therapeutic targets are defined as any protein, gene or other molecule...
Items per page:
1 - 10 of 231